О ВОПРОСАХ БЕЗОПАСНОСТИ ПРИМЕНЕНИЯ АНТИАРИТМИЧЕСКИХ ПРЕПАРАТОВ
Аннотация
Сообщение посвящено проблеме безопасности применения антиаримических препаратов. Часто при назначении антиаритмиков не учитываются их сложные межлекарственные взаимодействия, органоспецифичность, проаритмогенность, фармакокинетика и фармакодинамика, особенности применения в зависимости от пола и возраста, а также имеющейся фоновой кардиальной и экстракардиальной патологии, включая хроническую болезнь почек, а также лечение аритмий во время беременности.
Подробно освещены вопросы безопасности для пациентов, получающих антиаритмические препараты, стратификация риска с учетом доступных электрокардиографических параметров. Обсуждаются общие принципы ведения больных с проаритмиями, органоспецифической токсичности и другие аспекты безопасности. Особое внимание уделено побочным эффектам одного из распространенных антиаритмических препаратов – амиадорона. В частности, приведены данные о мониторинге функции щитовидной железы и оценке функции лёгких, что нередко является драматическими осложнениями терапии амиодароном.
Литература
1. Ватутин Н.Т., Тарадин Г.Г., Гриценко Ю.П. Поражение легких как осложнение терапии амиодароном. Пульмонология. 2016; 26 (2): 246-253. doi:10.18093/0869-0189-2016-26-2-246-253.
2. Ватутин Н.Т., Шевелёк А.Н., Дегтярева А.Э., Тарадин Г.Г., Гриценко Ю.П., Василенко И.В. Развитие повреждения легких при приёме амиодарона. Кардиология. 2016;8: 93-96. doi:10.18565/cardio.2016.8.93-96.
3. Allen LaPointe N.M., Lokhnygina Y., Sanders G.D. [et al.] Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. Am Heart J. 2013;166: 871-8.
4. Hohnloser S.H., Crijns H.J., van Eickels M. [et al.] Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360: 668-78. doi:10.1056/NEJMoa0803778.
5. Dan G.A., Martinez-Rubio A., Agewall S. [et al.] Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018;20(5): 731-732. doi:10.1093/europace/eux373.
6. Priori S.G., Blomstrøm-Lundqvist C., Mazzanti A. [et al.] 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace. 2015;17: 1601-87. doi:10.1093/europace/euv319.
7. Kirchhof P., Benussi S., Kotecha D. [et al.] 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18: 1609-78. doi:10.1093/ejcts/ezw313.
8. Elliott P.M., Anastasakis A., Borger M.A. [et al.] 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35: 2733-79. doi:10.1093/eurheartj/ehu284.
9. Boriani G., Savelieva I., Dan G.A. [et al.] Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society. Europace. 2015;17: 1169-96. doi:10.1093/europace/euv202.
10. Simantirakis E.N., Koutalas E.P., Vardas P.E. Arrhythmia-induced cardiomyopathies: the riddle of the chicken and the egg still unanswered? Europace. 2012;14: 466-73. doi:10.1093/europace/eur348.
11. Enriquez A.D., Economy K.E., Tedrow U.B. Contemporary management of arrhythmias during pregnancy. Circ Arrhythm Electrophysiol. 2014;7: 961-7. doi:10.1161/CIRCEP.114.001517.
12. Regitz-Zagrosek V., Blomstrøm-Lundqvist C., Borghi C. [et al.] ESC Guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J. 2011;32: 3147-97. doi:10.1093/eurheartj/ehr218.
13. Driver K., Chisholm C.A., Darby A.E. [et al.] Catheter ablation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol. 2015;26: 698-702. doi:10.1111/jce.12675.
14. Reiffel J.A. Inpatient versus outpatient antiarrhythmic drug initiation: safety and cost-effectiveness issues. Curr Opin Cardiol. 2000;15:7-11.
15. Zipes D.P., Camm A.J., Borggrefe M. [et al.] ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Com. Europace. 2006;8:746-837. doi:10.1016/j.jacc.2006.07.010
16. Roden D.M. Pharmacology and toxicology of Nav1.5-Class 1 anti-arrhythmic drugs. Card Electrophysiol Clin. 2014;6: 695-704. doi:10.3389/fphys.2017.00759.
17. Kawabata M., Yokoyama Y., Sasaki T. [et al.] Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers. Clin Pharmacol. 2015;7: 29-36. doi:10.2147/CPAA.S77021.
18. Drew B.J., Ackerman M.J., Funk M. [et al.] Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121: 1047-60. doi:10.1161/CIRCULATIONAHA.
19. Pedersen H.S., Elming H., Seibak M. [et al.] Risk factors and predictors of torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. Am J Cardiol. 2007;100: 876-80. doi:10.1016/j.amjcard.2007.04.020.
20. Myerburg R.J., Kessler K.M., Cox M.M. [et al.] Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation. 1989;80: 1571-9.
21. Antman E.M., Wenger T.L., Butler V.P. [et al.] Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81: 1744-52.
22. Hudzik B., Zubelewicz-Szkodzinska B. Amiodarone-related thyroid dysfunction. Intern Emerg Med. 2014;9: 829-39. doi:10.1007/s11739-014-1140-1.
23. Wiśniowska B., Tylutki Z., Wyszogrodzka G., Polak S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect—comprehensive overview of clinical trials. BMC Pharmacol Toxicol. 2016; 17:12. doi:10.1186/s40360-016-0053-1.
24. Connolly S.J., Dorian P., Roberts R.S. [et al.] Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295: 165-71. doi:10.1001/jama.295.2.165.
2. Ватутин Н.Т., Шевелёк А.Н., Дегтярева А.Э., Тарадин Г.Г., Гриценко Ю.П., Василенко И.В. Развитие повреждения легких при приёме амиодарона. Кардиология. 2016;8: 93-96. doi:10.18565/cardio.2016.8.93-96.
3. Allen LaPointe N.M., Lokhnygina Y., Sanders G.D. [et al.] Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. Am Heart J. 2013;166: 871-8.
4. Hohnloser S.H., Crijns H.J., van Eickels M. [et al.] Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360: 668-78. doi:10.1056/NEJMoa0803778.
5. Dan G.A., Martinez-Rubio A., Agewall S. [et al.] Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018;20(5): 731-732. doi:10.1093/europace/eux373.
6. Priori S.G., Blomstrøm-Lundqvist C., Mazzanti A. [et al.] 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace. 2015;17: 1601-87. doi:10.1093/europace/euv319.
7. Kirchhof P., Benussi S., Kotecha D. [et al.] 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18: 1609-78. doi:10.1093/ejcts/ezw313.
8. Elliott P.M., Anastasakis A., Borger M.A. [et al.] 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35: 2733-79. doi:10.1093/eurheartj/ehu284.
9. Boriani G., Savelieva I., Dan G.A. [et al.] Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society. Europace. 2015;17: 1169-96. doi:10.1093/europace/euv202.
10. Simantirakis E.N., Koutalas E.P., Vardas P.E. Arrhythmia-induced cardiomyopathies: the riddle of the chicken and the egg still unanswered? Europace. 2012;14: 466-73. doi:10.1093/europace/eur348.
11. Enriquez A.D., Economy K.E., Tedrow U.B. Contemporary management of arrhythmias during pregnancy. Circ Arrhythm Electrophysiol. 2014;7: 961-7. doi:10.1161/CIRCEP.114.001517.
12. Regitz-Zagrosek V., Blomstrøm-Lundqvist C., Borghi C. [et al.] ESC Guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J. 2011;32: 3147-97. doi:10.1093/eurheartj/ehr218.
13. Driver K., Chisholm C.A., Darby A.E. [et al.] Catheter ablation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol. 2015;26: 698-702. doi:10.1111/jce.12675.
14. Reiffel J.A. Inpatient versus outpatient antiarrhythmic drug initiation: safety and cost-effectiveness issues. Curr Opin Cardiol. 2000;15:7-11.
15. Zipes D.P., Camm A.J., Borggrefe M. [et al.] ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Com. Europace. 2006;8:746-837. doi:10.1016/j.jacc.2006.07.010
16. Roden D.M. Pharmacology and toxicology of Nav1.5-Class 1 anti-arrhythmic drugs. Card Electrophysiol Clin. 2014;6: 695-704. doi:10.3389/fphys.2017.00759.
17. Kawabata M., Yokoyama Y., Sasaki T. [et al.] Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers. Clin Pharmacol. 2015;7: 29-36. doi:10.2147/CPAA.S77021.
18. Drew B.J., Ackerman M.J., Funk M. [et al.] Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121: 1047-60. doi:10.1161/CIRCULATIONAHA.
19. Pedersen H.S., Elming H., Seibak M. [et al.] Risk factors and predictors of torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. Am J Cardiol. 2007;100: 876-80. doi:10.1016/j.amjcard.2007.04.020.
20. Myerburg R.J., Kessler K.M., Cox M.M. [et al.] Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation. 1989;80: 1571-9.
21. Antman E.M., Wenger T.L., Butler V.P. [et al.] Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81: 1744-52.
22. Hudzik B., Zubelewicz-Szkodzinska B. Amiodarone-related thyroid dysfunction. Intern Emerg Med. 2014;9: 829-39. doi:10.1007/s11739-014-1140-1.
23. Wiśniowska B., Tylutki Z., Wyszogrodzka G., Polak S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect—comprehensive overview of clinical trials. BMC Pharmacol Toxicol. 2016; 17:12. doi:10.1186/s40360-016-0053-1.
24. Connolly S.J., Dorian P., Roberts R.S. [et al.] Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295: 165-71. doi:10.1001/jama.295.2.165.
Опубликована
2018-09-22
Как цитировать
ВАТУТИН, Н. Т. et al.
О ВОПРОСАХ БЕЗОПАСНОСТИ ПРИМЕНЕНИЯ АНТИАРИТМИЧЕСКИХ ПРЕПАРАТОВ.
Университетская клиника, [S.l.], n. 3(28), p. 68-77, сен. 2018.
ISSN 1819-0464. Доступно на: <http://journal.dnmu.ru/index.php/UC/article/view/235>. Дата доступа: 24 ноя. 2024
doi: https://doi.org/10.26435/uc.v0i3(28).235.
Раздел
Обзоры
